A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia

References

• Hamblin T J. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33: 230–239
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Oscier D G, Young B J. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986; 39: 713–716
   PubMed Web of Science ®Google Scholar
• Catovski D, Goldman J M, Priesler H D. Chronic lymphocytic, prolymphocytic and hairy cell leukemia. Leukaemias, J M Goldman, H D Priesler. Butterworth, London 1984; 266–298
   Google Scholar
• Dearden C. Disease-specific complications of chronic lymphocytic leukemia. ASH Education Program Book 2008; 452
   Google Scholar
• Hall A M, Vickers M A, McLeod E, Barker R N. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005; 105: 2007–2015
   PubMed Web of Science ®Google Scholar
• Dameshek W, Rosenthal M C. The treatment of acquired hemolytic anemia. With a note on the relationship of periarteritis nodosa to hemolytic anemia. Med Clin North Am 1951; 35: 1423–1440
   PubMedGoogle Scholar
• Rosenthal M C, Spaet T H, Goldenberg H, Dameshek W. Treatment of acquired haemolytic anaemia with compound F acetate. Lancet 1952; 1: 1135–1140
   PubMedGoogle Scholar
• Neal T F, Jr, Tefferi A, Witzig T E, Su J, Phyliky R L, Nagorney D M. Splenectomy in advanced chronic lymphocytic leukemia: a single institution experience with 50 patients. Am J Med 1992; 93: 435–440
   PubMed Web of Science ®Google Scholar
• Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol 1999; 61: 98–102
   PubMed Web of Science ®Google Scholar
• Besa E C. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med 1984; 76: 209–218
   PubMed Web of Science ®Google Scholar
• Besa E C. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. Am J Med 1988; 84: 691–698
   PubMed Web of Science ®Google Scholar
• Hershko C, Sonnenblick M, Ashkenazi J. Control of steroid-resistant autoimmune haemolytic anaemia by cyclosporine. Br J Haematol 1990; 76: 436–437
   PubMed Web of Science ®Google Scholar
• Ruess-Borst M A, Waller H D, Muller C A. Successful treatment of steroid-resistant hemolysis in chronic lymphocytic leukemia with cyclosporine A. Am J Hematol 1994; 46: 375–376
   PubMed Web of Science ®Google Scholar
• Emilia G, Messora C, Bensi L. The use of cyclosporin-A in the treatment of B-chronic lymphocytic leukemia. Leukemia 1995; 9: 357–359
   PubMed Web of Science ®Google Scholar
• Sigler E, Shtalrid M, Goland S, Sthoeger Z M, Berrebi A. Intractable acute autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia successfully treated with vincristine-loaded platelet infusion. Am J Hematol 1995; 50: 313–315
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A. Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Semin Hematol 2004; 41: 234–245
   PubMed Web of Science ®Google Scholar
• Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004; 72: 79–88
   PubMed Web of Science ®Google Scholar
• Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005; 10: 79–93
   PubMed Web of Science ®Google Scholar
• Gupta N, Kavura S, Patel D, Janson D, Driscoll N, Ahmed S, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002; 16: 2092–2095
   PubMed Web of Science ®Google Scholar
• Mauro F R, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95: 2786–2792
   PubMed Web of Science ®Google Scholar
• Zent C S, Schwager S M, Reinalda M S, Hoyer J D, Jelinek D F, Tschumper R C, Bowen D A, Call T G, Shanafelt T D, Kay N E, Slager S L. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008; 141: 615–621
   PubMed Web of Science ®Google Scholar
• Myint H, Copplestone J A, Orchard J, Craig V, Curtis D, Prentice A G, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341–344
   PubMed Web of Science ®Google Scholar
• Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008; 111: 1820–1826
   PubMed Web of Science ®Google Scholar
• Eichhorst B F, Busch R, Hopfinger G, Pasold R, Helsel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891
   PubMed Web of Science ®Google Scholar
• Flinn I W, Neuberg D S, Grever M R, Dewald G W, Bennett J M, Paietta E M, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 2007; 25: 793–798
   PubMed Web of Science ®Google Scholar
• Kyasa M J, Parrish R S, Schichman S A, Zent C S. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003; 74: 1–8
   PubMed Web of Science ®Google Scholar
• Diehl L F, Ketchum L H. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25: 80–97
   PubMed Web of Science ®Google Scholar
• Stahl D, Lacroix-Desmazes S, Sibrowski W, Kazatchkine M D, Kaveri S V. Broad alterations of self-reactive antibody-repertoires of plasma IgM and IgG in B-cell chronic lymphocytic leukemia (B-CLL) and B-CLL related target-restricted autoimmunity. Leuk Lymphoma 2001; 42: 163–176
   PubMed Web of Science ®Google Scholar
• Treon S P, Anderson K C. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27(6 Suppl. 12)79–85
   PubMed Web of Science ®Google Scholar
• Willis F, Marsh J C, Bevan D H, Killick S B, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114: 891–898
   PubMed Web of Science ®Google Scholar
• Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007; 21: 511–514
   PubMed Web of Science ®Google Scholar
• Coles A J, Compston D A, Selmaj K W, Lake S L, Moran S, Margolin D H, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–1801
   PubMed Web of Science ®Google Scholar
• Giagounidis A A, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002; 69: 95–100
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Madueme H L, Wolf R C, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003; 78: 1340–1346
   PubMed Web of Science ®Google Scholar
• D'Arena G, Laurenti L, Capalbo S, D'Arco A M, De Fillippi R, Marcacci G, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006; 81: 598–602
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003; 44: 1951–1955
   PubMed Web of Science ®Google Scholar